Catalent Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 09/25/2023
Catalent Inc Stock Forecast and Price Target
The average price target of $73.00 for Catalent Inc's stock set by three distinguished analysts in recent weeks would represent a potential upside of approximately 59.32% from the last closing price in September, 2023 if reached by the end of the year. This potential increase is based on a high estimate of $100.00 and a low estimate of $58.00. Even if you are not interested in CTLT stock, it is still imperative to be aware of its competitors.
59.32% Upside
Catalent Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Catalent Inc has seen a decline in its Price, from $55.89 to $7.10 – a 87.29% decrease. In the next year, analysts believe that Fair Value will reach $83.99 – an increase of 1082.61%. For the next four years, the forecast is for Fair Value to grow by 1991.30%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
14
|
$552.32 | Buy/Sell | $333.19 | -27.58% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$160.26 | Buy/Sell | $179.95 | 12.63% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$32.98 | Buy/Sell | $44.13 | 59.64% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$105.84 | Buy/Sell | $99.57 | 11.49% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$59.16 | Buy/Sell | $80.99 | 40.30% |
Catalent Inc Revenue Forecast for 2023 - 2025 - 2030
Catalent Inc's Revenue has seen impressive growth In the last four years, rising from $2.52B to $4.83B – a growth of 91.74%. In the next year, analysts believe that Revenue will reach $5.17B – an increase of 7.09%. For the next four years, the forecast is for Revenue to grow by 34.22%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
13
|
$350.67 | Buy/Sell | $384.26 | -7.04% |
| ZTS Stock Forecast | Zoetis Inc | Outperform |
18
|
$177.72 | Buy/Sell | $209.70 | 15.35% |
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$834.64 | Buy/Sell | $796.73 | -6.31% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$37.50 | Buy/Sell | $60.73 | 54.67% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$170.77 | Buy/Sell | $244.18 | 46.98% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$9.71 | Buy/Sell | $13.70 | 39.03% |
Catalent Inc Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last four years, Catalent Inc's Free Cash Flow has seen an increase, rising from $30.00M to $364.00T. This represents a growth of 1213330946.67%. In the following year, 1 experts forecast Catalent Inc's Free Cash Flow will decrease by 100.00%, to $270.00M. In 2030, professionals predict that Catalent Inc's Free Cash Flow will decrease by 100.00%, to $699.00M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| UTHR Stock Forecast | United Therapeutics Corp | Outperform |
12
|
$224.06 | Buy/Sell | $280.69 | 31.66% |
| IONS Stock Forecast | Ionis Pharmaceuticals Inc | Outperform |
9
|
$42.67 | Buy/Sell | $52.42 | 17.18% |
| PRGO Stock Forecast | Perrigo Co PLC | Buy |
16
|
$32.19 | Buy/Sell | $47.75 | 47.56% |
Catalent Inc Net Income Forecast for 2023 - 2025 - 2030
In the last four years, Catalent Inc's Net Income has grown, moving from $137.00M to $519.00M – an increase of 278.83%. According to 1 prominent analysts, Catalent Inc's Net Income will fall by 19.85% in the next year, reaching $416.00M. Looking ahead to five years, experts forecast that Net Income will grow by 63.39%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$126.67 | Buy/Sell | $163.67 | 29.47% |
| NEOG Stock Forecast | Neogen | Hold |
16
|
$19.48 | Buy/Sell | $37.00 | 30.90% |
| CYTK Stock Forecast | Cytokinetics Inc | Outperform |
10
|
$30.00 | Buy/Sell | $62.67 | 100.00% |
Catalent Inc EBITDA Forecast for 2023 - 2025 - 2030
Catalent Inc's EBITDA has seen growth In the last four years, going from $522.00M to $727.00M – a gain of 39.27% In the next year, analysts believe that EBITDA will reach $1.13B – an increase of 54.88%. For the next five years, the forecast is forEBITDA to grow by 150.89%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$8.97 | Buy/Sell | $73.38 | 111.82% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£21.51 | Buy/Sell | £3.79 | -77.96% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$32.82 | Buy/Sell | $79.67 | 137.66% |
Catalent Inc EBIT Forecast for 2023 - 2025 - 2030
In the last three years, EBIT for Catalent Inc has grown by 157.68%, going from $293.00M to $755.00M. In the coming year, analysts are expecting an increase in EBIT, predicting it will reach $1.03B – an increase of 36.03%. Over the next five years, experts anticipate that EBIT growth for Catalent Inc will be 42.53%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$32.32 | Buy/Sell | $0.00 | -8.73% |
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$45.96 | Buy/Sell | $41.00 | -4.26% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Hold |
14
|
$8.53 | Buy/Sell | $12.60 | 46.54% |
Catalent Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Catalent Inc has seen a decline in its EPS, from $1.81 to $0.23 – a 87.29% decrease. In the next year, analysts believe that EPS will reach $2.72 – an increase of 1082.61%. For the next four years, the forecast is for EPS to grow by 1991.30%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$30.06 | Buy/Sell | $35.50 | 13.11% |
| LGND Stock Forecast | Ligand Pharmaceuticals | Outperform |
14
|
$58.86 | Buy/Sell | $195.43 | 169.28% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$150.96 | Buy/Sell | $170.08 | 15.92% |
.jpg)